Upstream Processing

CRL to buy WuXi for $1.6bn

CRL to buy WuXi for $1.6bn

By Nick Taylor

Charles River Laboratories (CRL) is to acquire WuXi PharmaTech for $1.6bn (€1.2bn), creating a global CRO capable of offering fully integrated services from molecule creation to first-in-human testing.

Follow us

Products

View more

Webinars